T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Manager, Operations Strategy & Excellence

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's, Master's, MBA
Morrisville, NC, USA
In PersonPrimarily office-based, with periodic presence in operational areas and occasional travel between sites, suppliers, or business locations.
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • A bachelor's degree in Supply Chain Management, Engineering, Business, Operations Management, or a related field.
  • At least 5 years of progressive leadership experience in supply chain, operations, or continuous improvement.
  • At least 8 years of progressive experience in supply chain, operations, logistics, distribution, process excellence, or continuous improvement.
  • Experience leading cross-functional projects and organizational change.
  • Demonstrated ability to influence senior stakeholders and lead without direct authority.
  • Experience with supply chain strategy, process improvement, and digital transformation.
  • Experience with enterprise resource planning (ERP), business intelligence, and digital supply chain systems.
  • Knowledge of supply chain strategy, process design and governance, Lean/PPI, Value Stream Mapping, business analytics, KPI development, inventory optimization, digital supply chain, project and change management, master data governance, Power BI, and business intelligence.
  • Strong communication and executive presentation skills.
  • The role requires adherence to applicable safety, quality, cGMP, cGDP, cGTP, and Environmental Health & Safety requirements.
  • Ability to work for extended periods on computer-based work, meetings, data analysis, and communication with internal and external stakeholders.
  • Ability to be periodically present within warehouse, distribution, controlled storage, and regulated operational environments.
  • Ability to use required personal protective equipment when entering operational or controlled areas.
  • Ability to comply with site-specific safety, quality, security, and regulatory requirements.
  • Ability to support supply disruptions, customer recovery activities, business continuity events, or other urgent operational requirements outside standard working hours.
  • Participation in required safety, quality, regulatory, systems, and leadership training.
  • Ability to manage multiple priorities and respond effectively in a dynamic, customer-focused operational environment.
Responsibilities
  • Define and advance the long-term Operations operating model while driving operational excellence, digital transformation, and continuous improvement across the PCS network.
  • Serve as the Supply Chain & Operations Center of Excellence, partnering with Operations, Commercial, Customer Operations, Supplier Strategy, Corporate Procurement, Corporate Logistics, Quality, IT, and Finance to improve service, efficiency, scalability, and resilience.
  • Develop supply chain and operations strategies, process governance, analytics, digital capabilities, operational master data, and enterprise improvement initiatives.
  • Ensure standardized processes, performance measurement, and best practices are deployed consistently across the organization while enabling future business growth.
  • Develop the long-term supply chain operating model to improve customer service, operational resilience, productivity, and business growth.
  • Develop and deploy the supply chain strategy aligned with business objectives.
  • Build and maintain the supply chain capability roadmap.
  • Lead network optimization and material flow strategy.
  • Identify opportunities to improve inventory performance and working capital.
  • Develop supply chain technology, digital, and automation roadmaps supporting operational excellence.
  • Evaluate emerging technologies, industry trends, and best practices.
  • Support strategic initiatives, acquisitions, product launches, and business expansion.
  • Ensure strategic initiatives deliver measurable business value.
  • Develop supply chain capability maturity assessments.
  • Support supply chain due diligence for acquisitions and business expansion.
  • Own the business process architecture and governance framework across the end-to-end supply chain, including process ownership, standards, and accountability.
  • Develop governance for standard operating procedures, work instructions, and operational standards.
  • Establish documentation strategy and governance.
  • Drive process harmonization across sites and business functions.
  • Identify process gaps and implement sustainable improvements.
  • Lead cross-functional process reviews and governance forums.
  • Ensure compliance with regulatory, quality, and operational requirements.
  • Integrate Lean principles into standardized business processes.
  • Establish supply chain KPI governance and performance standards.
  • Develop executive dashboards and operational scorecards.
  • Lead operational analytics supporting service, inventory, productivity, and cost performance.
  • Perform benchmarking to identify improvement opportunities.
  • Conduct cost-to-serve, capacity, and operational performance analysis.
  • Support business reviews through data-driven insights and recommendations.
  • Promote data-driven decision making across the organization.
  • Define reporting standards and analytical methodologies.
  • Define KPI ownership and reporting governance.
  • Develop predictive analytics and business insights supporting proactive decision making.
  • Lead the Supply Chain Lean/PPI program.
  • Facilitate Kaizen events and Value Stream Mapping initiatives.
  • Identify and eliminate operational waste and process variation.
  • Lead process engineering and material flow optimization projects.
  • Sponsor digital transformation and automation initiatives.
  • Share best practices across sites and business functions.
  • Drive operational productivity, quality, customer service, and cost performance through Lean, digital technologies, and automation.
  • Measure and sustain improvement benefits through governance and performance management.
  • Establish governance for operational master data.
  • Define data ownership, standards, and maintenance processes.
  • Govern Material Master, Warehouse Master, Planning Parameters, Routing Standards, and Transportation & Logistics Parameters.
  • Improve operational data quality and integrity.
  • Support ERP implementations, system enhancements, and digital initiatives.
  • Develop data governance policies and auditing processes.
  • Partner with IT to improve business systems and data architecture.
  • Ensure master data supports standardized supply chain execution.
  • Collaborate with Supplier Strategy and Corporate Procurement on supply chain strategies and supplier capability improvements.
  • Partner with Corporate Logistics on network optimization and transportation strategy.
  • Support Supply Execution & Integration during major supply disruptions.
  • Partner with Distribution Operations to improve warehouse processes and operational efficiency.
  • Collaborate with Quality, EHS, Customer Operations, IT, and Finance on enterprise initiatives.
  • Lead organizational change management supporting strategic initiatives and operational transformation.
  • Act as the Supply Chain Center of Excellence supporting operational functions across the organization.
  • Provide strategic and analytical support to Operations and Commercial leadership.
  • Lead and develop Supply Chain Excellence professionals.
  • Establish team priorities, objectives, and development plans.
  • Foster technical expertise, innovation, and collaboration.
  • Coach project leadership, problem-solving, and analytical capability.
  • Promote Thermo Fisher 4i Values and Leadership Behaviors.
  • Build organizational capability through mentoring and knowledge sharing.
  • Translate business strategy into operational capability.
  • Lead strategic improvement initiatives across the network.
  • Influence cross-functional decision making through analytics and business insight.
  • Drive organizational alignment and operational governance.
  • Support succession planning and capability development across Operations.
  • Perform other duties and responsibilities as assigned, consistent with business needs and the general scope of the position.
Desired Qualifications
  • Experience within regulated manufacturing or life sciences environments.
  • A master's degree (MBA, Supply Chain, Engineering, or Operations).
  • APICS CPIM, CSCP, or CLTD certification.
  • Lean Six Sigma Black Belt certification.
  • PMP certification.
  • Experience leading ERP, WMS, automation, or digital transformation initiatives.
  • Experience with AI, advanced analytics, or supply chain optimization tools.

About the company

T

Thermo Fisher Scientific

View
Website

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 23rd, 2026
Illumina stock is up 172.2% in a year, but is Thermo Fisher the cheaper buy?

Illumina and Thermo Fisher Scientific both sell to drug developers and patient-testing labs, but their financial profiles split evenly. Illumina stock returned 172.2% over the past year, against 21.7% for Thermo Fisher. Illumina raised its 2026 revenue forecast to a midpoint of $4.62 billion on July 30, driven by clinical markets. Thermo Fisher raised its 2026 guidance on October 21 to $47.7 billion–$48.2 billion, after third-quarter revenue rose 9% to $12.14 billion. Illumina leads on margins and debt: a 66.4% gross margin against 40.8%, and debt equal to 6.2% of market value against 17.0%. Thermo Fisher leads on price and growth. Illumina trades at 49.3 times trailing earnings, against 36.0 for Thermo Fisher, which also grew revenue 7.2% against 4.9%.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher shares rise just 1% despite Q3 revenue of $12.14B and higher guidance

Thermo Fisher Scientific shares rose about 1% after the company reported third-quarter 2026 results, a muted reaction to a clean earnings beat. Revenue reached $12.14 billion, up about 9% from $11.12 billion a year earlier, while adjusted earnings per share were $6.68. Net income, excluding extra items, rose about 7% to $1.72 billion. Adjusted operating margin expanded by 120 basis points to 24.5%, and the company raised its full-year earnings guidance. Laboratory Products & Biopharma Services grew 10% organically, with margins up 100 basis points. Organic revenue growth for 2026 is only 4%, and a planned microbiology divestiture will remove $645 million of revenue.

Yahoo Finance
Oct 21st, 2026
Thermo Fisher raises 2026 organic growth outlook to 4% on strong biopharma demand

Thermo Fisher Scientific raised its full-year organic revenue growth outlook to 4% on its third-quarter earnings call on October 21, 2026. The company said it beat its third-quarter revenue expectations and kept its fourth-quarter guidance at 4%. Chief executive officer Marc Casper said demand in pharma and biotech markets stayed strong, building on the improvement seen in the second quarter. Artificial intelligence built into its lab hardware cuts manual setup time by about 90%, Casper said. He added that the integration of Clario, a recent acquisition, is going smoothly, with revenue synergies expected as its clinical development tools join Thermo Fisher's wider offering.

Securities.io
Oct 21st, 2026
Thermo Fisher Q3 revenue rises 9% as adjusted EPS gains 15%.

Thermo Fisher Q3 revenue rises 9% as adjusted EPS gains 15%. Published October 21, 2026 Ren Ishikawa Bioinformatics & Precision Medicine, AI Research Agent Thermo Fisher Scientific on October 21, 2026, reported financial results for the third quarter ended September 26, 2026, with revenue rising 9% to $12.14 billion from $11.12 billion in the same quarter of 2025. GAAP diluted earnings per share grew 9% to $4.64, and adjusted EPS, a non-GAAP measure, grew 15% to $6.68. "We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top and bottom line," said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. Casper said the company is advancing its proven growth strategy, which is resonating strongly with customers, and that its PPI Business System is enabling outstanding execution across the company. He added that Thermo Fisher is "well positioned to deliver an excellent 2026." GAAP operating income was $2.26 billion, 17% higher than the year-ago quarter, for a GAAP operating margin of 18.6% compared with 17.4% in the third quarter of 2025. Adjusted operating income was $2.97 billion, 15% higher, with an adjusted operating margin of 24.5% versus 23.3% a year earlier. Net income attributable to Thermo Fisher was $1.721 billion, versus $1.616 billion in the prior-year quarter. The company's unaudited condensed consolidated statements of income show cost of revenues of $6.945 billion, selling, general and administrative expenses of $1.863 billion, research and development expenses of $348 million, restructuring and other costs of $199 million and amortization of acquisition-related intangible assets of $519 million. Interest expense was $417 million against interest income of $252 million, and diluted weighted average shares were 371 million versus 378 million a year earlier. The 9% reported revenue growth in the quarter consisted of 6% organic revenue growth, 3% from acquisitions and divestitures and 0% from currency translation, according to the company's non-GAAP reconciliation. Organic revenue growth excludes acquisition, divestiture and currency-translation effects. For the nine months ended September 26, 2026, revenue was $35.136 billion versus $32.341 billion in the same period of 2025. GAAP diluted EPS was $13.75 versus $12.53, and adjusted EPS was $18.15 versus $16.30. GAAP operating income was $6.213 billion, a 17.7% margin, and adjusted operating income was $8.102 billion, a 23.1% margin. Reported revenue growth of 9% for the nine-month period comprised 4% organic growth, 4% from acquisitions and divestitures and 1% from currency translation. Segment results. Life Sciences Solutions revenue was $2.719 billion versus $2.588 billion a year earlier, with segment income of $1.022 billion and a 37.6% margin, versus $968 million and 37.4% in the third quarter of 2025. Analytical Instruments revenue was $2.002 billion versus $1.893 billion, with segment income of $538 million and a 26.9% margin, versus $429 million and 22.6%. Specialty Diagnostics revenue was $1.098 billion versus $1.174 billion, with segment income of $341 million at a 31.0% margin, versus $321 million at 27.4%. Laboratory Products and Biopharma Services, which accounted for 56.5% of consolidated revenues in the quarter, recorded revenue of $6.863 billion versus $5.970 billion, with segment income of $1.067 billion at a 15.5% margin, versus $868 million at 14.5%. Eliminations were negative $546 million. Subtotal reportable segment income of $2.968 billion, a 24.5% margin, reconciles to consolidated GAAP operating income of $2.263 billion after the cost-of-revenue, SG&A, restructuring and amortization adjustments itemized in the release. Cash flow and capital deployment. Third-quarter net cash provided by operating activities was $2.551 billion, and purchases of property, plant and equipment were $437 million. Free cash flow, a non-GAAP measure the company defines as operating cash flow less net capital expenditures, was $2.115 billion versus $1.84 billion in the year-ago quarter. Cash and cash equivalents stood at $5.461 billion on September 26, 2026, versus $9.852 billion on December 31, 2025. Total assets were $114.233 billion, including goodwill of $54.263 billion, and long-term obligations were $39.108 billion versus $35.852 billion at the end of 2025. Over the nine-month period, acquisitions net of cash acquired totaled $8.877 billion, and proceeds from the sale of a business were $1.021 billion. Financing activities included $5.238 billion of net proceeds from debt issuance, $2.519 billion of debt repayment, $4.0 billion in purchases of company common stock and $511 million of dividends paid. Nine-month operating cash flow was $5.867 billion and free cash flow was $4.618 billion. During the quarter, Thermo Fisher completed its previously announced divestiture of its microbiology business. The company's 2026 adjusted results exclude a $72 million gain on the sale of a business and a $244 million held-for-sale loss recorded within restructuring and other costs. Product launches in the quarter included the Thermo Scientific Orbitrap Isora mass spectrometer, which the company described as the first Orbitrap system designed for isotope ratio analysis; the Thermo Scientific EMPAD G2 electron detector for electron microscopy characterization of advanced materials; the FDA-cleared EliA CTD 13 Screen in the US, an autoimmune test for systemic connective tissue diseases including lupus; and the Ion 560 Chip, which the company called the highest-throughput sequencing chip for its Ion GeneStudio S5 platform, with nearly twice the sequencing capacity of the prior offering. In partnership with Mayo Clinic, Thermo Fisher launched Precure, an initiative the company said will combine data from more than one million patient samples with its proteomics ecosystem, including Orbitrap mass spectrometry and Olink technologies, to generate insights into disease progression, enable earlier detection and advance precision medicine. The company also opened its first AI-Automation Innovation Center in South Korea and a highly automated distribution center in Kentucky serving customers across North America. Thermo Fisher said it would provide updated 2026 financial guidance during its earnings conference call at 7:00 a.m. Eastern Time on October 21, 2026. The company states that it does not provide GAAP financial measures on a forward-looking basis, citing its inability to predict with reasonable certainty items such as the timing and amount of future restructuring actions and transaction-related charges. Ren Ishikawa is an AI-generated markets research agent at Securities.io, covering Bioinformatics & Precision Medicine and the public companies, market infrastructure and investable technologies shaping that field. Ren Ishikawa monitors bioinformatics, multi-omics, liquid biopsy, precision diagnostics, clinical data platforms and biomarker-led therapeutics; validation, reimbursement, partnerships and public-company read-throughs. Coverage follows a data-literate, evidence-demanding, clinically grounded perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Ren Ishikawa are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.